Institute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist, Department of Automation, Tsinghua University, 100084, Beijing, China.
TCM Network Pharmacology Department, Tianjin Key Laboratory of Early Druggability Evaluation of Innovative Drugs, Tianjin International Joint Academy of Biomedicine, 300457, Tianjin, China.
J Ethnopharmacol. 2023 Mar 1;303:115930. doi: 10.1016/j.jep.2022.115930. Epub 2022 Nov 17.
Weifuchun capsule (WFC) is a traditional Chinese patent medicine for chronic atrophic gastritis (CAG) in clinic. However, the mechanism of action of WFC for CAG still remains unclear due to its complex composition.
The study was projected to uncover the mechanism of action of WFC and the corresponding pharmacodynamic substance of WFC against CAG as well as providing a standard example for the research of traditional Chinese medicine (TCM) from the perspective of the network and the system.
We identified the compounds of WFC through LC-MS/MS analysis and performed a systematic network targets analysis for WFC in the treatment of CAG which thoroughly described the mechanism of action of WFC for CAG. Based on analysis integrating omics data and algorithms, we focused on the specific immune regulatory role of WFC in the treatment of CAG, especially on a hub pathway, Toll-like receptor signaling pathway and thus deciphered the role of WFC in immune regulation, anti-inflammation and mediation of HES6. In experiments part, MNNG-GES-1-cell line and rat models were used to validate our findings.
In this study, compounds of WFC are identified through LC‒MS/MS and network target analysis is performed to dissect the specific immunoregulatory effect as well as mediation of HES6, a newly discovered biomolecule related to gastritis carcinoma progression, of WFC on CAG through the Toll-like receptor signaling pathway. Based on cell line and rat models, we verify the mechanism of action of WFC for CAG in inhibiting inflammatory cytokines, regulating immune cells like T cells and macrophages, related genes including TLR2 and CD14. It is also validated that WFC inhibits the expression of HES6 (P < 0.05).
Based on the combination of computational strategy and experiments, our study offers a comprehensive analysis to reveal the role of WFC in regulating immune response, inhibiting inflammation in the treatment of CAG, and provides a standard example for the research of TCM from the perspective of the network and the system.
胃复春胶囊(WFC)是临床上用于治疗慢性萎缩性胃炎(CAG)的一种中药专利药。然而,由于其复杂的组成,WFC 治疗 CAG 的作用机制仍不清楚。
本研究旨在揭示 WFC 治疗 CAG 的作用机制及相应的药效物质,为从网络和系统角度研究中药提供标准范例。
我们通过 LC-MS/MS 分析鉴定了 WFC 的化合物,并对 WFC 治疗 CAG 进行了系统的网络靶标分析,全面描述了 WFC 治疗 CAG 的作用机制。基于整合组学数据和算法的分析,我们专注于 WFC 在治疗 CAG 中的特定免疫调节作用,特别是在一个关键途径—— Toll 样受体信号通路,从而揭示了 WFC 在免疫调节、抗炎和 HES6 介导中的作用。在实验部分,我们使用 MNNG-GES-1 细胞系和大鼠模型来验证我们的发现。
在这项研究中,我们通过 LC-MS/MS 鉴定了 WFC 的化合物,并通过网络靶标分析,揭示了 WFC 通过 Toll 样受体信号通路对 CAG 的特定免疫调节作用以及对新发现的与胃炎癌进展相关的生物分子 HES6 的介导作用。基于细胞系和大鼠模型,我们验证了 WFC 抑制炎症细胞因子、调节 T 细胞和巨噬细胞等免疫细胞、TLR2 和 CD14 等相关基因的作用机制。同时,也验证了 WFC 抑制 HES6 的表达(P<0.05)。
基于计算策略和实验的结合,本研究提供了一种全面的分析,揭示了 WFC 在调节免疫反应、抑制 CAG 炎症中的作用,并为从网络和系统角度研究中药提供了一个标准范例。